MANNKIND CORP Deferred Costs, Current
MANNKIND CORP (MNKD) had Deferred Costs, Current of $22.74 million as of 2016-06-30, per its 10-Q/A filed 2016-08-10.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredCostsCurrent · last filed 2017-03-16
- 2016-06-30: Deferred Costs, Current $22.74M.
- 2016-03-31: Deferred Costs, Current $13.54M.
- 2015-12-31: Deferred Costs, Current $13.54M.
| Period end | Deferred Costs, Current |
|---|---|
| 2016-06-30 | $22.74M 10-Q/A · filed 2016-08-10 |
| 2016-03-31 | $13.54M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $13.54M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |